LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced that it has submitted its Marketing Authorization Application
(MAA) to the European Medicines Agency (EMA) for neratinib. The
potential indication is for the extended adjuvant treatment of
HER2-positive early stage breast cancer that has previously been treated
with trastuzumab (Herceptin®)-based adjuvant therapy. The submission is
based upon the ExteNET Phase IIImore...